Here, to further assess the potential benefit of GO in both young and elderly adult CBF-AML, we retrospectively analyzed data from 265 CBF-AML patients who received first-line IC with or without GO, registered in the databases of the German Study Alliance Leukemia (SAL), the German AML Cooperative Group (AMLCG), and the Czech Leukemia Study Group for Life (CELL). Here, CEBPZ is linked to acute myeloid leukemia.